Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
argenx
Pharma
Argenx preps next potential Vyvgart nod after ph. 3 win
With its latest trial readout for under-the-skin efgartigimod, argenx is adding another feather to the FcRn blocker’s cap.
Fraiser Kansteiner
Aug 17, 2026 10:52am
J&J data set up Imaavy for expansion to treat anemic disorder
Jun 11, 2026 10:36am
Orphan drug sales to surge past $400B in 2032: report
Mar 12, 2026 8:20am
Argenx's Vyvgart posts ph. 3 win in ocular myasthenia gravis
Feb 26, 2026 11:18am
FDA untitled letters target drug ads from Novo, argenx, Sobi
Feb 10, 2026 11:42am
Argenx telegraphs CEO switch as chief drug Vyvgart rolls ahead
Jan 5, 2026 2:12pm
